Literature DB >> 9931415

Dissociable and nondissociable forms of platelet-activating factor acetylhydrolase in human plasma LDL: implications for LDL oxidative susceptibility.

M R McCall1, M La Belle, T M Forte, R M Krauss, Y Takanami, D L Tribble.   

Abstract

Platelet-activating factor acetylhydrolase (PAF-AH) is transported by lipoproteins in plasma and is thought to possess both anti-inflammatory and anti-oxidative activity. It has been reported that PAF-AH is recovered primarily in small, dense LDL and HDL following ultracentrifugal separation of lipoproteins. In the present studies, we aimed to further define the distribution of PAF-AH among lipoprotein fractions and subfractions, and to determine whether these distributions are affected by the lipoprotein isolation strategy (FPLC versus sequential ultracentrifugation) and LDL particle distribution profile. When lipoproteins were isolated by FPLC, the bulk (approximately 85%) of plasma PAF-AH activity was recovered within LDL-containing fractions, whereas with ultracentrifugation, there was a redistribution to HDL (which contained approximately 18% of the activity) and the d>1.21 g/ml fraction (which contained approximately 32%). Notably, re-ultracentrifugation of isolated LDL did not result in any further movement of PAF-AH to higher densities, suggesting the presence of dissociable and nondissociable forms of the enzyme on LDL. Differences were noted in the distribution of PAF-AH activity among LDL subfractions from subjects exhibiting the pattern A (primarily large, buoyant LDL) versus pattern B (primarily small, dense LDL) phenotype. In the latter group, there was a relative depletion of PAF-AH activity in subfractions in the intermediate to dense range (d=1.039-1.047 g/ml) with a corresponding increase in enzyme activity recovered within the d>1.21 g/ml ultracentrifugal fraction. Thus, there appears to be a greater proportion of the dissociable form of PAF-AH in pattern B subjects. In both populations, most of the nondissociable activity was recovered in a minor small, dense LDL subfraction. Based on conjugated dienes as a measure of lipid peroxidation, variations in PAF-AH activity appeared to contribute to variations in oxidative behavior among ultracentrifugally isolated LDL subfractions. The physiologic relevance of PAF-AH dissociability and the minor PAF-AH-enriched oxidation-resistant LDL subpopulation remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9931415     DOI: 10.1016/s0005-2760(98)00177-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

1.  Uremia alters HDL composition and function.

Authors:  Michael Holzer; Ruth Birner-Gruenberger; Tatjana Stojakovic; Dalia El-Gamal; Veronika Binder; Christian Wadsack; Akos Heinemann; Gunther Marsche
Journal:  J Am Soc Nephrol       Date:  2011-07-29       Impact factor: 10.121

Review 2.  Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications.

Authors:  Giuseppe Maiolino; Valeria Bisogni; Giacomo Rossitto; Gian Paolo Rossi
Journal:  World J Cardiol       Date:  2015-10-26

3.  The elevation of apoB in hypercholesterolemic patients is primarily attributed to the relative increase of apoB/Lp-PLA₂.

Authors:  Constantinos C Tellis; Eliza Moutzouri; Moses Elisaf; Robert L Wolfert; Alexandros D Tselepis
Journal:  J Lipid Res       Date:  2013-10-03       Impact factor: 5.922

4.  HDL is the major lipoprotein carrier of plasma F2-isoprostanes.

Authors:  Julie M Proudfoot; Anne E Barden; Wai Mun Loke; Kevin D Croft; Ian B Puddey; Trevor A Mori
Journal:  J Lipid Res       Date:  2008-12-02       Impact factor: 5.922

5.  Unraveling the PAF-AH/Lp-PLA2 controversy.

Authors:  Diana M Stafforini; Guy A Zimmerman
Journal:  J Lipid Res       Date:  2014-07-09       Impact factor: 5.922

6.  Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia.

Authors:  Kiyohito Arai; Alexina Orsoni; Ziad Mallat; Alain Tedgui; Joseph L Witztum; Eric Bruckert; Alexandros D Tselepis; M John Chapman; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2012-05-24       Impact factor: 5.922

Review 7.  Small dense low-density lipoprotein particles: clinically relevant?

Authors:  Ronald M Krauss
Journal:  Curr Opin Lipidol       Date:  2022-03-11       Impact factor: 4.616

Review 8.  Molecular Model of Plasma PAF Acetylhydrolase-Lipoprotein Association: Insights from the Structure.

Authors:  Prabhavathi Srinivasan; Brian J Bahnson
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-08

9.  HDL functionality and cardiovascular outcome among nondialysis chronic kidney disease patients.

Authors:  Kathrin Untersteller; Sabine Meissl; Markus Trieb; Insa E Emrich; Adam M Zawada; Michael Holzer; Eva Knuplez; Danilo Fliser; Gunnar H Heine; Gunther Marsche
Journal:  J Lipid Res       Date:  2018-05-22       Impact factor: 5.922

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.